The Acquisition That Looked Accretive

What accretion means here EPS accretion is an accounting outcome, not a value outcome. It depends on the financing mix, the target's earnings, the synergies assumed, and the price paid relative to earnings. A board should ask: accretive relative to what, and at what risk?

Decomposing the synergy claim

• $12m of synergies on $21m of EBITDA is a 57% uplift. That is a large claim and should be evidenced customer by customer.
• $9m of the $12m is revenue synergy, the least reliable category. Revenue synergies require the combined entity to win customers it has not yet won, at prices and volumes that do not yet exist. They should be excluded from the base case and shown only as upside.
• $3m of cost synergy is more credible but still requires a cost-to-achieve figure, which the paper omits.

The arithmetic to demand

• Base case with cost synergies only: EBITDA of roughly $24m.
• Downside with no synergies and a 10% revenue attrition from customer overlap: EBITDA of roughly $19m.
• Add integration costs (typically one to two times annual synergies) and the deal looks materially less attractive.
• Show EPS impact under each case, and show the return on invested capital versus Harborline's cost of capital over five years. If ROIC stays below WACC for three years, the deal destroys value even if EPS rises.

Assumptions carrying most risk

1. Revenue synergies of $9m.
2. The 9% cost of debt, which may reprice if leverage rises.
3. No customer attrition assumption, despite 22% concentration in the largest customer.
4. No integration cost.

The question the board should ask: "If we are wrong about the revenue synergies, what does this deal do to our balance sheet and our covenant headroom?" That question was never answered.

Leverage

• Pro forma net debt of 3.4x EBITDA is a step change from 1.8x. On the downside case (EBITDA around $19m combined, before any Harborline EBITDA contribution), the multiple is worse than the headline.
• The board must see the covenant package: maintenance covenants, headroom under base and downside cases, and the consequences of a breach. If the downside case leaves less than 20-25% headroom, the deal is fragile.
• Interest cover and the refinancing profile matter as much as the multiple. A 9% cost of debt on $120m is roughly $10.8m of annual interest before fees.

Concentration

• Harborline's largest customer is 22% of revenue. The target's customer base is not disclosed in the paper. Combined concentration could be materially higher.
• If the large customer is also a customer of the target, the revenue synergy case is partly double-counted and partly at risk from a single procurement decision.

Conditions before signing

1. A base case using cost synergies only, and a downside case with zero synergies and specified customer attrition, both signed by the CFO.
2. Customer-by-customer evidence for the $9m revenue synergy, with named customers and confirmed volumes.
3. A full integration cost estimate and a funded integration budget.
4. A financing plan with covenant headroom tested against the downside case.
5. A walk-away price and a clear statement of what is being paid for goodwill versus hard assets.
6. A completion mechanism that adjusts price if specified customers are lost before completion.

Vote against if: the board is asked to sign before seeing the downside case; if covenant headroom under the downside is inadequate; or if the price is not reduced to reflect the removal of unverified revenue synergies. "Strategic logic" is not a substitute for a number.

Signing a paper with no downside case and no integration costs is a lapse in the CFO's core duty of objectivity. The board should treat it as a signal about the quality of financial information it receives generally, not just about this deal.

Immediate steps

• Ask the CFO directly, in the absence of the CEO, to walk through the assumptions and to state which figures are his own analysis and which came from advisers or the deal team.
• Ask for the underlying model, not the summary, and have the audit committee or an independent adviser review it.
• Establish whether the CFO raised concerns internally and was overruled. If so, the board needs to know, because it bears on whether the CEO respects the information rights of the board.

Structural steps

• Require that major transaction papers carry a standard template: base, downside and severe downside cases; sensitivity tables; capital and covenant impact; integration costs; and a statement of key judgements.
• Require that the CFO's sign-off includes an explicit statement that the paper presents a balanced view, and that dissent or uncertainty is recorded.
• Ensure the CFO has a direct reporting line to the audit committee for assurance matters, and that the committee meets the CFO without the CEO at least annually.
• Consider whether the CFO's incentives are tied to deal completion. If so, that is a conflict that should be disclosed to the board.

The governance point: The board does not need to distrust the CFO, but it must not depend on a single source for the numbers behind its largest decisions. Independent challenge on a $180m transaction is proportionate, not adversarial.